Paulson is definitely not a showoff guy like Chanos. Even at the height of the financial crisis when his fund was profiting back on the meltdown, it was the press that reported about him. I never heard of Paulson until then. He is not the type that would like to go onto CNBC once a month and tout his portfolio.
Sentiment: Strong Buy
looks like some accumulation going on today. normally VRX would pull back some after a jump but today and volume is low. I think traders are moving in slowly but knowing that they can break news soon.
Ackerman in the meantime is too busy dealing with CMG.
Only for those that shorted from $30 down to mid $20s. Some of them still have some gains that they will play wait for see if this is just a one day rally.
Walgreen better pay up and get their staff to call the insurance company before dispensing the drugs.
About time. It is a triple whammy today for the shorts. The Phase III trial results, Walgreen's comment as well as Street Diligence telling people to short their bonds but long on stocks.
The FDA is supposed to issue its verdict on 7/21 about the eye drug on glaucoma.
I think we would run for another day. This time is the short squeeze for those that sold in the mid 20s.
VRX submitted in July 2015 for approval and it has been almost a year so it is due for review and approval. This could potentially be a cash cow and good news for eye patients.
This will take this back up to the mid 30s. He probably already covered last week and started nibbling at some long positions.
I'm more enthusiatic to hear about the Phase II trial of the new eye medicine for Glaucoma. THink about FDA approval by 7/21.